Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Cara Therapeutics Rose 11.3% in July

By Maxx Chatsko - Aug 5, 2019 at 10:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The development-stage pharma company started an important clinical trial.

What happened

Shares of Cara Therapeutics ( CARA -4.50% ) rose over 11% last month, according to data provided by S&P Global Market Intelligence. The clinical-stage company announced multiple milestones for an oral formulation of its lead drug candidate, Korsuva.

In July, the oral formulation started a phase 2 study to evaluate its safety and effectiveness in treating pruritus (read: severe itching) in patients with atopic dermatitis (read: a condition marked by red and itchy skin). Cara Therapeutics also announced that an interim statistical review of a phase 2 study in pruritus in patients with chronic kidney disease (CKD) didn't require expanding the size of the trial, which stands at 240 patients. That suggests it's powered to deliver statistical significance and can remain on the original timeline for completion.

Shares would have ended the month even higher if not for a public stock offering that raised $145.5 million in gross proceeds at the end of July. The business ended March with $134 million in cash. 

A man in a suit drawing an ascending step chart.

Image source: Getty Images.

So what

Cara Therapeutics is developing Korsuva to treat itching in patients with CKD, chronic liver disease, and atopic dermatitis. The drug candidate crushed its most important phase 3 trial in late May, but that was for an injectable formulation aimed at CKD patients and is partnered with Fresenius Medical Care. The company is also developing a more convenient oral formulation of the drug candidate to treat a broader set of patient populations. Cara Therapeutics owns the global rights to the oral formulation.

Therefore, recent news that the three phase 2 clinical trials (including one that initiated in late June) for the oral formulation of Korsuva are progressing through development is giving investors even more to cheer about. That's also why the business decided to pad its balance with more cash, as the increased activity of the maturing pipeline will be expensive to manage.

Now what

Investors have rewarded Cara Therapeutics with a $1 billion market cap for its progress in recent years. The injectable formulation of Korsuva appears destined for marketing approval, and with the world's leading dialysis provider as a partner, it has the opportunity to get off to a fast start. It will be another year or two before investors can be as confident in the wholly owned oral formulation, but the business is on a promising trajectory.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
CARA
$12.31 (-4.50%) $0.58
Fresenius Medical Care AG & Co. KGaA Stock Quote
Fresenius Medical Care AG & Co. KGaA
FMS
$30.42 (0.13%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.